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Qbjeerives. We sour it to examine, augiograpbicaliy, the long 
term fate of a large number of mainly venous coronary bypass 
grafts and to eorreiate graft patency and disease with patient 
survival and reoperatiou. 
Background. Much is known about bypass graft patency and 
disease, but tb precise relation between graft fate and patient 
outcome has not been substantiated and documented. 
Methods. A total of 1,388 patients underwent a first coronary 
artery bypass graft procedure at a mean age of&9 years, 234 bad 
a second bypass procedure at a mean age of 533 years, and 15 had 
a third bypass procedure,at a mean age of 58.2 years during the 
25year period from 1969 to 1994. Most were male military 
personnel or veterans; 12% were 539 years old. Of 5,284 grafts 
placed, 91% were venous and % arterial. Angiograms were 
performed on 5,065 (98% of surviving) grafts early, on 3,993 grafts 
at 1 year and on 1,978 grafts at 5 years after operation; otber 
examinations were also performed up to 22.5 years after opera- 
tion, and 353 grafts were examined after 215 years. Grafts were 
graded for patency and disease. The status of all patients was 
known at the study’s end. 
Resuk The perioperative mortality rate was 1.4% for an 
isolated first coronary bypass procedure, 6.6% for reoperation. 
Vi-in graft patency was 88% early, 81% at 1 year, 75% at 5 years 
inud 50% at Z-15 years; when suboptimal grafts, graded II, were 
excluded from caiculation, the proportion of excellent grafts, 
The fate of coronary artery bypass grafts depends on many 
factors, including technical faults in harvesting, handling and 
fashioning the conduits; thrombosis; myointimal hyperplasia; 
fibrosis; and a rapidly progressing variety of atherosclerosis. 
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91996 bv the American Colle‘ee of Cardioloe, 
graded 8, decrease*% to 40% after 112.5 years. After the early 
study, the vein graft occlusion rate was 2.1Wyear. Internal 
mammary artery graft patency was significartly better but de- 
creased with time. Vein graft disease appeared by 1 year and tbe 
rate accelerated by 12.5 years, involving 4g% of grafts at 5 years 
and 81% at 215 years; 44% of the latter grafts were narrowed 
>XJ%. Survival of all patients was 93.6% at 5 years, 81.1% at 10 
years, 62.1% at 15 years, 46.7% (1SO patients) at 20 years and 
38.4% (25 patients) at 23 years after operation. Survival decreased 
as age increased, but curves approximated “normaP’ life expect- 
ancy for older patients. Survival curves at all ages showed a 
steeper decline after 7 years. The rate of reoperation increased 
behveeu 5 years and 10 to 14 years, then decreased to staMe Ieveis. 
Coronary atheroembolism from vein grafts was the major cause of 
morbidity and mortality associated with reoperatiou. Vein graft 
patency and disease were temporally and closely related to 
reoperation and survival. 
Conclusions. Coronary bypass graft dk:ase and occlusion are 
common after coronary artery bypass grafting and increase with 
time. They are major determinants of clinical prognosis, specifi- 
cally measured by reoperation rate and survival. Intraoperative 
graft atheroembolism was a major reoperation hazard. Reopera- 
tion is definitely worthwhile but entails identifiable risks that 
must be dealt with. 
(J Am Co11 Car&o1 1996;28:616-26) 
Nvvasokwa (1) recently reviewed the extensive published data 
very well. The nature of our hospital permitted an attempt to 
correlate evolving graft morphology with clinical outcome 
through systematic sequential, selective, multiple plane angio- 
graphic studies. In 1978, we (2) described patency grading of 
1,400 consecutive grafts early after operation and of 1,132 of 
these 1 year later. Subsequently, graft defects considered to be 
due to disease were also graded, and in 1986 we (3) reported 
on 1,179 vein grafts, each studied early and 1 and 5 years after 
operation. We (4) reported a similar study of 741 vein grafts 
examined in sequence h6.5 years (mean 9.6) after operation in 
1991. Our principai findings were 1) Vein graft occlusion rates 
were -11% early and -50% late after operation. 2) Intimal. 
irregularities appeared at 1 year and progressed to involve 
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some 75% of grafts late after operation. 3) As disease spread 
over the graft surface, lesions gained bulk and protruded into 
the lumen, resulting in graft stenosis or occlusion. 4) Disease 
increased relentlessly once it appeared, but some apparently 
healthy grafts were unexpectedly found to be diseased or 
occluded in later studies. 
In the presen: report, we describe the angiographic appear- 
ance of 5,065 assorted coronary bypass grafts (92% venous, 9% 
arterial), not studied in specific sequences but each examined 
at least once during exactly 25 years. In addition, we have 
correlated bypass graft fate with reoperation rates and with 
patient survival, demonstrating that the clinical outcome of 
mronary bypass grafting depends primarily on graft integrity, 
and we have attempted to define the relation between this 
determinant and its consequences. 
Methods 
institutional background. Coronary artery disease is the 
major nontraumatic cause of serious morbidity and mortality 
in Canadian military personnel. Myocardial revascularization 
began at the National Defence Medical Centre (NDMC), 
Ottawa, with the Vineberg procedure ($6) in 1965, continuing 
with coronary artery bypass grafting from 1969 (7). However, 
operations requiring cardiopulmonary bypass required brief 
patient transfer to cardiac surgery facilities of the Ottawa Civic 
Hospital, which later became the University of Ottawa Heart 
Institute. Nevertheless, most postoperative care and all diag- 
nostic and follow-up activities have taken place at NDMC (8). 
Military medical devolution and decentralization hzve recently 
led to major institutional downsizing (9), and this determined 
our’series’ end on December 31, 1994. 
Patients. There were 1,388 patients; 79% were military 
personnel, only 12 were women. At the first coronary artery 
bypass graft procedure, the patients ranged in age from 27 to 
79 years (mean 48.9), at the second bypass procedure from 32 
to 83 years (mean 53.3) and at the third procedure from 45 to 
71 years (mean 58.2). There were 167 patients (12%) 539 
years old; 8 of these had a second operation by this age. A 
previous report (10) described results of coronary artery bypass 
grafting in 138 patients 539 years old. There were 954 patients 
(69%) aged 40 to 54 years and only 267 (19%) 255 years old. 
Thirty-five patients had had a previous Vineberg procedure. 
Since 1982, 159 patients have also undergone percutaneous 
transluminal coronary angioplasty of one or more coronary 
arteries or bypass grafts, 38 before and 121 after the bypass 
procedure. The angioplasty procedures were performed on 103 
grafts, 95 venous; on 15 (16%) of the 95 for restenosis. Three 
patients undenvent heart transplantation; ail are currently 
surviving, one at 10 years after transplantation. The first 
coronary bypass operation was performed on December 18. 
1969 and the last on December I4, 1994. All operatio,;a are 
reported and none performed elsewhere is included. The 
initial patient undenvent reoperation in I977 and 1993 and is 
currently well. 
Operations. Of the 1,637 coronary bypass procedures, 
1,388 were: first, 234 were second and 15 were third operations; 
1,154 patients had only one bypass procedure, 219 had only 
two and I5 had three procedures. Fifteen percent of all 
operations were repeat procedures, but 17% of the patients 
had more 9S?n one procedure. We believe that <12 of our 
patients have had a repeat coronary bypass procedure else- 
where. The operations were performed by 11 surgeons; 1 
performed 40% of the procedures and 4 colleagues collectively 
performed 54% Normotbcrmic anoxic cardiac arrest was used 
initially and coid potassium cardioplegia in the second half of 
the series. Coronary artery stenosis ~50% was the indication 
for grafting. A total of 4,801 saphenous vein and 466 in situ 
internal mammary (internal thoracic) artery grafts were 
placed. The right gastroepiploic artery was utilized ver)i late for 
six in situ grafts. There were four free internal mammary artery 
and three free inferior epigastric grafts. Expanded polytetra- 
fluoroethylene conduits were used four times, Optimal use of 
internal mammary artery grafts was delayed; 90% of these 
grafts were placed after 1985 and 75% were placed at a iirst 
bypass procedure. Both internal mammary arteries were used 
in 12% of cases during 1985 to 1989 and in 23% of cases in the 
last 5 years, an important advance (11,12). Of internal mam- 
mary artery grafts, 67% were to the left anterior descending 
artery, 13% to its diagonal branches, 15% to marginocircum- 
flex branches and 5% to right coronary artery branches. 
Adjuvant coronary endarterectomy was performed during 344 
first operations and 23 reoperations; multiple endarterecto- 
mies were performed in 11% of the-e cases. 
Complete revascularization was 2 constant aim. We (2) 
previously described 414 patients who had a mean of 3.3 grafts 
per primary operation before November 1976. In the present 
series, 3.4 grafts were placed at a first operation, 2.4 grafts at a 
second and 2.5 grafts at a third operation. Twenty-six percent 
of 5,284 grafts were to the trunk or branches of the right 
coronary artery, 27% were to the left anterior descending 
coronary artery, 19% to diagonal and 0.4% (19 cases) to septal 
branches and 28% to the marginocircumflex system. Propor- 
tionately fewer marginocircumflex grafts were placed at a 
second and fewer yet at a third operation. Most bypass gmf@ 
had a single distal anastomosis; we (13) have reported 2 
disappointing experience with sequential grafts. Saphenous 
veins were harvested with minimal manipulation and held in 
papaverine/saline solution. Full reulizatim that pc!att but dis- 
eased vein grafts in situ pose major recpmrion prohfems came 
slowly. This critica& impta~tt $34) tqk w$li be discussed iater 
Antiplatelet age&s. Since 1969, we havt- given antiplatelet 
agents to alI patients with coronary artery disease. Initially, we 
used dipyridamole and high dose aspirin, occasionally substi- 
tuting sulfinpyrazone. Except in urgent cases, snlfinpyrazone, 
instead of aspirin, was used for 5 days before operation to 
decrease perioperative bleeding; the usual routine ws rsinsti- 
tuted about 3 days postoperatively. Recently, dipyridamole has 
been given with aspirin only before angiography, and routine 
aspirin dosage is now convestional. These agents have not 
been evaluated formally. 
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Follow-up angiography. Examinations included two-plane 
left ventriculcgraphy and four-plane selective coronary and 
bypass graft angiography. Radiopaque thread rings marked 
aortic graft ostia. The Judkins technique was most oiten used, 
with 8F catheters (Cordis Corporation). A Judkins tight coro- 
nary catheter was used for most aortic and many internal 
mammary artery htubations; ihe internal mammary artery 
catheter was frequently useful and the Bl (CB) catheter was 
sometimes invaluable. Graft occlusion was never inferred 
solely from difficulty in intuba:ion: supporting coronary or 
aortic flood evidence was required tar Uris determination. 
We initially used megiumine diarrizoate as the contrast 
medium, later iopamidol. Selective vein grafl angiography 
entails risk. We (15) previously reported coronary vein graft 
spasm 31 times in >lO,OOO selective opacifications; graft 
GCC~US~GII occurred in three patients, two of these sustaining 
nonfatal myocardial infarction. The sole death due to 
follow-up angiography in the present study jand in aft illit’ 
experience) was a result of fulminating anaphylaxis in a patient 
who had had four uncomplicated angiograms, also using 
meglumine diatrizoate, during the previous 12 years. Our 
mortality rate for a!1 coronary angiography is an acceptable 
(16) 0.08%. 
Graft angiograms and grading. Of the total of 5,284 grafts, 
101 ;iere lost to study because of perioperative death; the 
remaining 5,183 grafts were available for study, and 5,065 
(98%) of these were examined early: 3,993 at 1 year and 1,978 
at 5 years after operation. Our plan to repeat postoperative 
angiography every 5 years indefinitely was thwarted by lack of 
funds, although some patients returned repeatedly a: their own 
expense for follow-up. Angiograms were obtained up tG 22.5 
years after operation. However, the number of vein grafts 
studied was <SO after 17.5 years, so thGSe vein grafts examined 
at 215 years have been consolidated at 353, and intema! 
mammary artery grafts examined at 25 years have been 
consolidated at 123. We (4) previously reported an unexpected 
increase in vein graft abnormality between 5 and 10 years 
postoperatively, “the 7.5 year phenomerlon,” thought to be due 
in part to “late” presentation of patients with covert symptoms 
at 5 years. Consequently, vein graft findings between principal 
quinquennial assessment points are assigned intermediately. 
Previous reports dealt with grafts that were all examined in a 
ccmmcn temporal sequence. The present results relate to 
angiographic findings in all grafts at ail examinations, and the 
number reported is thus greater. 
Definitions of bypass graft patency (2) and grades of disease 
(3) are summarized in Table 1. All grades relate to the worst 
appearance in four-plane views and were visually determined 
subjectively. Grades, assigned by four experienced cardiclo- 
gists, have been reproducible (2-4,10,13,17). 
Data handling and statistical methods. Information was 
examined in a computerized relational data base of our own 
design (produced by Neodyne Consulting Limited, Ottawa, 
Ontario, Canada). Life table and chi-square analyses were 
done by standard methods (18). We knew the survival status of 
Table 1. Definitions of Graft Grades, Assessed by 
Four-Plane Angiography 
Grade KkfinItion 
Patency 
A Excellent graft with unimpaired runoff 
I3 Stenosis reducing caliber of proximal or distal anastomoses 
or trunk to ~50% of the grufied coronoq; arlery. Overall 
graft B grade was determined by the lowest of the three 
specific site grades 
0 Occlusion 
Disease 
I No intimal irregularity 
II Irregularity of -30% of estimated intl%al smface 
III irregularity of >50% of estimated intimal surface 
HP High profile lesion produces >50% stenosis @graft 
LP Low profile lesion produces <50% stenosis ofgrafi 
Grades A, B and 0 assess graft flow. Grades I, II, 111, HP and LP reflect 
disease severity. 
all patients on December 31, 1994 but have not attempted 
actuarial analysis by cause Gf death. 
Results 
Perioperative mortality; myocardial infarction. Periopera- 
tive mortality was defined as death from any cause during the 
entire stay at either hospital. Thirty-nine perioperative deaths 
yielded an overall mortality rate of 2.3%. However, 36 of the 
total group of 1,388 patients underwent coronary artery bypass 
grafting in association with another major cardiac procedure, 
such as valve replacement, and the mortality in this group was 
11.1%. Excluding these 36, but including those who had 
coincident repair of ventricular aneurysm (6% of the remain- 
ing patients), the mortality rate was 1.4% for a first coronary 
bypass procedure. This rate increased to 6.6% for all reopera- 
tions, including 2 of 15 pericperative deaths for a third bypass 
procedure. We (10,17) have previously reported no perioper- 
ative deaths associated with a first bypass procedure in 118 
patients with silent myocardial ischemia, and none in 138 
patients 539 years old. There were no perioperative deaths for 
167 first operations at ages ~39 years in the present series. 
Perioperative myccardial infarction was monitored only for 
reoperations. However, we (19) previously reported 56 infarc- 
tions (7.8%) complicating a first bypass procedure in 717 
patients. The infarction was trarrsmural in 23 (41%) of 56 of 
those patients and 2 of the 23 died; coronary endarterectomy 
increased rhe infarction rate by 170%. The incidence of 
infarction is probably similar for the present study. 
Vein graft patency. In all, 4,801 vein grafts were fashioned 
and 4,592 of these were examined early, 3,706 at 1 year and 
1,889 at 5 years after operation and scme at other times. Table 
2 Lists patency grades. The patency rate was 88% early after 
grafting but decreased to 75% at S years and to 50% at ~12.5 
years. The venous graft occlusion rate was 2.f%/year after the 
early examination. Patency loses its cachet when grade B grafts 
are eliminated; grade A grafts decreased to 40% of the 580 
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Table 2. Vein Graft Patency Grades on Follow-Up Angiography (first, second and third operations combined) 
Early 1 Year 2.5 Years 5 Years .._,. 
Total grafts w;mmined 4,592 3,706 469 1,869 
Graft grade 
A 3,728 (81%) 2,825 (76%) 303 (65%) 1,309 (696) 
B 299 (7%) 182 $8) 29 (6%) 109 @%I,) 
AtB 4,027 (~8%) 3,007 (81%) 332 (71%) 1.418 (75%) 
0 565 (12%) 699 (19%) 137 (29%) 4?1(25%) 
Date presented are number (%) of grafts. Graft patency grades are defined in Table 1. 
1.5 Years IO Years 12.5 Years 215 Years I---- 
495 856 227 353 
238 (48%) 448 (52%) !al (40%) 141(40%?0) 
60 (12%) 71 (8%) 21 19%) 36 (10%) 
298 (bm) 519 (mj 111(49%) 177 (SO%j 
197 (40s) 337 (40%) I16 (5s) 176 (50%) . . 
grafts examined at ~12.5 years. Twelve percent of all patent 
grafts were graded B at 15 years. Early vein grafts were graded 
B primarily because of distal anastomotic defects, later mainly 
for graft trunk narrowing. At the early examination, the 8.2% 
incidence of B grades for marginal grafts was significantly 
higher (p < 0.05) than the 6.2% incidence rate for right, 5.8% 
for left anterior descending and 5.3% for diagonal vessels. This 
difference has been noted (2) previously, and may be due to 
technical difficulty with the distal anastomosis. Also continning 
a previous observation (4), left anterior descending artery vein 
grafts were occluded early less often (p < 0.005) than were 
grafts to other vessels. This overall difference (p < 0.05) 
persisted at 1 and 5 years; even at 10 years, rates of occlusion 
of grafts to the left anterior descending and diagoaal arteries 
were lower (p < 0.05) than for other grafts. 
Arterial graft patency. Patency grades for internal mam- 
mary artery grafts are shown in Table 3. The 95% early internal 
mammary artery graft patency rate was better rban the 88% 
rate for’vein grafts, but 10% of the arterial grafts were grade B 
grafts. A learning curve effect may distort this number. During 
the 15 years to the end of 1984, 44 internal mammary artery 
grafts were examined early; 40 (91%) of these were patent and 
4 (9%) were graded B. These grafts were fashioned by the most 
experienced surgeons. During the next 5 (learning) years 211 
(93%) of 226 internal mammary artery grafts were patent, but 
30 (13%) were grade B. In the 5 years to the end of 1994,180 
(97%) of 186 internal mammary artery grafts were patent, and 
only 11(6%) were grade B. The B grades were usually assigned 
because of distal anastomotic internal mammary artery de- 
Table 3. Internal Mammary Artery Graft Patencv Grades 
on Follow-Up Angiography (first, second and third 
operations combined) 
Early Intermediate Late 
Total grafts examined 4.56 320 123 
Graft grade 
A 386 (85%) 267 (83X) 94 (7i%j 
B $5 (looq 23 (3%) 4 (3) 
AtB 431 (PiA) 291(9&) 98 tp.l%~ 
0 25 (5%) 29 (9%) 25 (2Whj 
Data presented are iiumber (g5) of grafts. Because of the smaller numkr cf 
internal mammary artery grafts, the grouping of follow-up data points ditkrs 
from that used for vein gratr patency in Table 2. Early = up to h mouths; 
Intermediate = 1 year and 2.5 years; fate = 25 years, Graft patency grades are 
defined in Table 1. 
fects, but there were some lengthy trunk defects, little in&t- 
enced by vasoactive drugs at angiography and perhaps due to 
operative trauma. Late internal mammary artery grade A 
grafts decreased to 77%, apparently not because of atheroscle- 
rosis. However, only 123 internal mammary artery grafts were 
examined late, mandating cautious interpretation of these 
results. Similarly, there were too few other arterial grafts for 
patency analysis, although five of six in situ right gastroepiploic 
grafts were impressively g&e A and one was grade B in early 
selective angiograms. 
Vein graft disease and fate. Atherosclerosis is rare in 
native internal mammary arteries (20) and was not found in 
internal mammary artery grafts. However, Table 4 shows 
intimal abnormalities appearing in vein grafts 1 year after 
operation and steadily increasing, until 239 (83%) of 288 
patent grafts were diseased at ~12.5 years. Curve B in Figure 
1 reveals the suddenness of attack of vein graft disease after 2.5 
postoperative years, and Table 4 shows that the incidence of 
the more extensive grade III disease outstrips that of grade II 
disease after 5 years. Furthermore, high pr&iIe lesions (pro- 
ducing stenosis ~50%) were present in 106 (44%) of 239 
diseased grafts and 37% of allI,atenr grafts at r12,5 years, the 
steady increase with time seen in curve C of Figure 1. 
Increasing lesion bulk clearly complicated extension of disease 
in the mural plane. The interrelation of vein graft patency, 
disease and occlusion, the last two rising together in curves A 
and B of Figure 1, is obvious, as is the inexorable wastage of 
nondiseased patent grafts in curve D. The message is malign 
and powerful. 
§urvivai atler a first cormwy bypass procedure. The 
survival data on all 1,388 patients after the first coronary artery 
bypass graft procedure, is shown tii IdWE: J =K ‘- --F;L’- i q-3 c*zp$?(f -4 of 
Figure 2. At 15 years, the proportion surviving was 81 D/o: at 15 
years 62%, at 20 years 47% and at 23 years 38% (25 survivors). 
The curve declines graduaily to -I years postoperatively, with 
a steeper decline thereafter. The data are classified by age into 
the three panels of Figure 3, based on data in Table 5. All’ 
curve slopes increase at 5 ro 7 years postoperatively. Survivd 
times of patients 539 years old are better than those of older 
patients, particularly at ages ~55 years The panels display 
population life expectancy curves for comparable Canadian 
men (21). Survival data for subjects 539 years aid are also 
plotted against comparable data reported by Certler er al. (22), 
in a 1964, 15-year follow-up study of 92 medically managed 
patients ~40 years old. ,:I ,:t ,( + 
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Table 4. Vein Bypass Graft Disease on Follow-Up Angiography (first, second and third operatio:ls combined) --” -- 
Patent grafts 
iNot diseased (I) 
Diseased 
II 
III 
II + III 
High profile lesions 
Proportion of diseased grafts 
Proportion of patent grafts 
Early 1 Year 
4,027 3,007 
4,027 (100%) 2,812 (94%) 
0 138 (5%) 
0 57 (2%) 
0 195 (7%) 
0 19 (10%) 
0 19 (0.6%) 
2.5 Years 
332 
294 (86%) 
32 (10%) 
16 (5%) 
4s (14%) 
6 (13%) 
6 (2%) 
5 Yeah 
1,418 
731 (52%) 
372 (26%) 
315 (22%) 
687 (4S%j 
291(42%) 
291(21%) 
7.5 Years 
29s 
87 (29%) 
s2 (‘28%) 
129 (43%) 
211(71%) 
7lj34%) 
71(24%j 
10 Years 
519 
119 (23%) 
178 (34%) 
222 (43%) 
400 (77%) 
125 (31%) 
125 (24%) 
12.5 Years 
jil 
16 (14%) 
30 (27%) 
65 (59%) 
95 (86%) 
43 (45%) 
43 (39%) 
915 Years 
177 
33 (19%) 
4.5 (2.5%) 
99 (56%) 
144 (81%) 
63 (44%) 
63 (36%) 
Data presented are number (%) of grafts. Disease grades are d&ed in Table 1. 
Survival after reoperation. At 10 and 15 years after oper- 
ation, the survival rate was 72% and 57%, respectively, for a 
repeat cFeration (curve B, Fig. 4), compared with 81% and 
6270, respectively, for all operations (curve A, Fig. 2). Figure 4 
shows the survival curves after the most recent bypass proce- 
dure of patients having only a primary procedure and of those 
having a reoperation. Early differences relate to perioperative 
mortality, but later disparities are slight, especially at >lO 
years. However, Figure 5 reveals the significant value of 
reoperation, when survival from the first bypass procedure, 
rather than from the last operation, is considered. 
Indications for reoperation. Stable and unstable angina 
were equally represented in the groups with a first and a repeat 
bypass procedure. However, the incidence of unstable angina 
doubled before the second procedure and affected all 15 
p;rtients before the third procedure. Some 20% of patients did 
not have angina before either their first or second bypass 
procedure. In a previous series (17) of 723 consecutive opera- 
tions, the incidence of asymptomatic patients was 16%. Ditfer- 
ences between those asymptomatic patients and patients with 
angina, including differences in long-term survival (23) were 
insignificant. Angiograpbic indications for reoperation in the 
present study were bypass graft failure in 80% of cases, failure 
combined with new native coronary disease in 12% and progres- 
sion of native artery disease alone in 8%. Bid grafts were 
occluded in 51% of cases. An as.: +zling order of occlusion rate 
was seen in left anterior descending (U%), diagonal (46%), right 
(52%) and marginocircumflex (60%) coronary artery grafts. Fifty 
percent of patent grafts were healthy; disease was extensive 
(grade III) in 69% of the other 50%. High profile lesions (~53% 
graft stenosis) were seen in 51% of the grade II (moderate 
disease) grafts and in 67% of grade JII (severe disease) grafts. 
Timing of reoperation and mor@dity and mortality. The 
cumulative incidence of reoperation appears in curve D, 
Figure 2. The actual annual rate of reoperation (not displayed) 
increased significantly 5 years after the first coronary bypass 
procedure, plateaued at IO to 14 years and then decreased to 
a lower but steady level. However, a repeat operation was 
performed in 31 patients within 6 manths of the first bypass 
procedure, in 40 patients within 12 months and in 53 patients 
A=occluded grafts at angiography 
B=all patent diseased grafts 
Gpatent high profile diseased grafts 
D=all patent non-diseased grafts 
Figure 1. Vein graft discase and occlusion. The graft 
occlusion rate was Z.l%/year after the first postopera- 
tive study. All categories of graft disease are included. 
High profile disease produces SO% graft stenosis. 
Note the increasing disease attack rate after 2.5 years. 
CABG = coronary artery bypass grafting. 
I 2.5 5 7.5 IO 12.5 15 
examination time in years since CABG 
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Table 5. Smvival After a First Coronary Artery Bypass Procedure Compared With That in the Series of Rahimtoola et ai. (54) and in the 
Coronary Artery Surgery Study (CA%) (55) 
I_.~. -. _ ..-_ 
5 Years 10 Years 15 Years 20 Years 23 Years 
.r 
2 . ,_ ,. L 
NO. Survival NO. Swiva! 1’0. Survival No. Survival NO. suwival 
Present series: $388 pat&s 1,226 93.6% 928 81.1% 556 62.1% 150 46.7% 25 38.4% 
(99% men, mean age 48.9 years) 
Age group 
539 yean 154 95% 119 85% 86 6S% 36 55% 
40 to 54 years 872 95% 693 84%~ 411 64% 98 46% 
35 years 200 85% 106 68% 9 47% 30% 
Rahimtoola et al.: late cohort, 1974 to 89% 74% 56% (i, (38%)* 
1988 (5,468 men, mean age of total 
cohort [7,026] 61.1 C 9.9 years) 
CASS 1974 to 1979 6,096 89% 4,921 73% 272 52% 
(6,922 men, mean age 54.6 f 8.5 years) 
*nvcnty-year value for entire 1969 to 198Rgend~r-lm~~~c cohort. Data presenied are number of patients a;d survival rate. 
within 24 months. There were no (O%), one (2.5%) and two 
(3.8%) perioperative deaths in each of these groups, respec- 
tively. The early operations were mainly in the first years of the 
series. The perioperative mortality rale was 7.1% for reopera- 
tions after 24 months, but it was 11.8% (10 of 85) for those 
performed >lO years after the first operation. 
The presence of diseased but patent grafts, particularly 
those with high profile lesions (~50% graft stenosis), increased 
reoperation morbidity and mortality. The incidence of myocar- 
dial infarction and perioperative death in patients with healthy 
or occluded grafts, or both, was insignificantly different from 
that in patients undergoing a first bypass procedure. However, 
the incidence increased fivefold in patients who underwent 
reoperation with one or more diseased patent grafts. Only 1 of 
16 deaths related to reoperation was of noncardiac origin 
(pancreatitis with splenic vein erosion). However, 9 (60%) of 
15 cardiac deaths were ,due to proved or strongly suspected 
intraoperative coronary atheroembolism. The latter was previ- 
ously demonstrated (24) angiographically in a survivor of 
reoperalion. In our patients who had a myocardiaf infarction, 
there was a highly significant correlation between graft disease 
with high profile lesions and atheroembolism. Eight of nine 
patients with a fatal infarction had grade Ill disease and all 
nine had high profile lesions. Twenty-one percent of myocar- 
dial infarctions that occurred at reoperation were fatal, Pre- 
dictably, mortality rose with the interval between operations, 
correlating with the rising incidence of patent but diseased 
grafts. Perioperative deaths tripled as the interoperative inter- 
val increased from <5 years to 5 to 10 years and rose fourfold 
after 10 years. 
Graft status after reoperation. All grafts in survivors of the 
bypass procedure were studied early. Of 406 vein grafts, 78% 
Figure 2. Survival of all 1,388 patients after a first 
coronary artery bypass graft procedure, reopera- 
Cons and graft fate. Standard actuarial ‘nethods 
were used to construct reoperalion czrve D, as for 
E 
g 
the survival curve A. Perioperative deaths are o 
included. Note the change in the slope of cunre A 4l- 
at -9 years. This figure summarizes the study’s 
findings. 
20 -- 
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39 & younger 55 & older 
1 Mifc expectancy 40 y old A=life expectancy 62 y old 
B=suwival of pt 55&clder 
Figure 3. Age-related survival after coronary artery by- 
pass grafting. Data in present study (curve B) compared 
with age-matched life expectancy for Canadian men (21) 
(curve A) and with that of young men -with coronary 
disease treated medically before 1964 described by Gertler 
ct al. (22) (curve C). hrote the change in curve B slopes at 
5 to 7 years. pt = patient. 
were grade A, 6% grade B (84% patent) and 16% were 
occluded. Of 111 internal mammary artery grafts, Sl% were 
grade A, 12% grade B (93% patent) and 7% were occluded. 
Graft fate and patient outcome. The interrelation between 
coronary bypass graft disease and occlusion, on the one hand, 
and reoperation and patient scr-,+al, on the other, is displayed 
in Figure 2, which summarizes the salient findings of this study. 
Discussion 
The 1978 editorial comment (25) that “graft occlusion is 
uncommon and most patients who do well do not undergo 
post-operative coronary angiography,” was promptly chal- 
lenged by the angiographic description (2) of a large number of 
consecutive coronary bypass grafts, with occlusion rates of 11% 
early and 19% at 1 year after operation. The graft occlusion 
rate in the present study was 12% for 4,592 saphenous vein 
grafts and 5% for 456 internal mammary artery grafts early 
after operation, rising to 51% for vein grafts after 12.5 years 
and 20% ai late internal mammary artery examinations. This is 
a considerable problem. 
Bypass graft disease. Perioperative occlusion of bypass 
grafts may be due to thrombosis resulting from !ocalized 
platelet dysfunction at the site of intimal damage, but it is later 
associated with atherosclerosis (14,26-37). Although patho- 
logic changes are similar in both, venous bypass graft disease 
does not parallel in severity atherosclerotic progression in 
native vessels (14), as accelerated vein graft atherosclerosis is 
characterized by instability and the fragility of late lesions. 
Intimal damage is followed by smooth muscle proliferation, a 
A=suwinl of 1154 patients having only primary CAE$G 
B=survival of 234 patients having 249 repeat CABG 
7 
.>- 
5 
uf 60. 
2 Figure 4. Survival after repeat (B) versus primary (A) 
B 
L coronary artery bypass grafting (CABG). Perioperative deaths are included. Survival time.s are from the most recent 
40 procedure. Year, number of survivors and percent survivors 
15 
are listed. 
A z&f 
1OY 
710 y1 
E5% 
;9 
20 - ‘92.5% 78.0% 42.5% 
B 172 
80.2% 770% 54637% 
10 
43.5% 
0. ,/,,I 8 ,,/a I ,/,,/,,/ 
0 5 
Years st”ce%t recent CAB0 
16 20 
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complex interaction between endothelium and platelets, the 
presence of lipids in “foam cells,” and the appearance of 
plaques, that differ in character by degree of fibrosis, lipid 
deposition, thrombosis and, occasionally. late calcification. 
Late thrombosis may occur (3s) in vein grafts with nonathero- 
sclerotic intimal hyperplasia, but it is uncommon. Thrombus 
forms slowly or suddenly after a “plaque accident”’ (plaque 
rupture) (39,40) in a coronary artery or bypass graft (41,42). 
Atheroembolism occurs spontaneously or with cardiovascular 
manipulation at reoperation (36,43), leading to coronary oc- 
clusion (24), often lethal. Results of gratt biopsres and autopsy 
studies attest to the frequency of atherosclerosis in older 
grafts; lesions have been noted (34) in 71% of grafts examined 
6 to 12 years postoperatively. 
Early angiographic findings are problematic. Myointimal 
hyperplasia and thrombus may present diagnostic difficulties 
(26). Our attribution of atherosclerosis to vein graft irregular- 
ities seen 1 year after operation (4) has been questioned (27), 
and the condition has been ascribed to localized myointimal 
hyperplasia. Nevertheless, vein graft atherosclerosis before 1 
year has been described histologically (30:31). However, high 
profile defects were seen at 1 year in only 0.5% of patent grafts 
in an earlier series (4) and in 0.6% of patent grafts in the 
present study. We have chosen to use consistent criteria to 
interpret angiographic findings, which are similar at earlier and 
later times. We believe that attribution to atherosclerosis of 
changes observed in sequential angiograms accords with gen- 
eral pathologic and angiographic opinion. Grondin et al. (44) 
have provided excellent descriptive terms. including “irregular 
wall,” “plaque, ” “conventional stenosis,” “spur diaphragm” 
and “cauliflower”. Sequential study pictures of “low profile” 
disease, which proliferates in the mural plane, evolving to 
heaped up “high profile” obstructive lesions, similar to the 
angiographic atherosclerotic progression in native coronary 
arteries, have supplemented these observations. 
A 1974 Montreal Heart Institute report (45) noted pre- 
sciently that “the attrition rate [of these grafts] may be 
progressive. Therefore, it is imperative to obtain long-term 
angiographic fol!ow-up in patients with coronary vein grafts. 
Such studies may help determine the fate of the saphenous 
vein in the aorto-coronary position. . . .” These words highlight 
the extensive studies in this field from other centers, particu- 
larly the work done in Cleveland, Montreal and Houston 
(14,33,35-X$43-53). Our projects have differed only in focus, 
and the results are in accord with and complement those of 
others. 
Bypass graft fate. Our internal mammary artery grafts did 
better than vein grafts hr the short term (patency rate 95% vs. 
88%) but less well in the long term, when the proportion ui 
grade A internal mammary artery grafts decreased from 85% 
early to 77% late. The striking decrease in grade B grafts from 
10% early to 3% late, coincided with the increase to an 
occlusion rate of 20% at ~5 years. However, the limited 
long-term data in Table 3 may not just@ didactic conclusions. 
A technical defect, usually at the distai anastomosis, is 
probably the most important factor in perioperative bypass 
A= 234 patients having 249 repeat CABG 
8=1131 patients having only me CABG 
A ;&I joy 218 :o 2 
98.7% 
20 - 
93.9% 7k.896 EQ.7% 
B 
E% 
710 
79.4% %% 48384% 
Figure 5. Overall survival of patients having more than one coronary 
artery bypass graft procedure. This graph includes all patients surviving 
the first bypass procedure and compares the overall wsirw~from the 
first bpass procedure of the 234 patients (group A) who had a later 
reoperation, with that of the 1,131 patients (group R) who hd only 
one bypass procedure. Those who died perioperatrvely at the first 
bypass procedure are excluded. because they were not at risk for 
reoperation. Reoperation mortality appears in the curve for group A at 
the approximate times that might be expected from reoperation times, 
noted in the text. It appears that overall survival fron the tim:: of the 
first bypass procedure is enhanced in patients (group A) undergoing 
reoperation. 
graft occlusion. B graft grades were assigned i:‘2-4) early after 
operation in SO% to 90% of cases because of distal defects. 
Our previously reported l-year occlusion rati: for grade B 
grafts (2) was 24% compared with 6% for gra!le A grafts, so 
grading is prognostically potent, Later vein gaft occlusion 
reflects developing graft atherosclerosis, but it may occur 
unexpectedly (3,4). Five years after operation, 50% of the 
patent vein grafts were diseased; this rate incmased to 83% at 
~12.5 years, with almost 50% of the lesions producing >50% 
graft stenosis. 
Sutival. Our survival data are displayed in Figures 2 to 5. 
Comparison with results reported (53-5.5) in other long-term 
studies is hindered by ditTerences in patient age and other 
disparities. For instance, only 6.3% of the patients of Rahirn- 
toola et al. (54) were 544 years old, whereas 12% in our series 
were 130 years old, with a wider discrepancy at later ages. 
Nevertheless, allowing for study differences but taking account 
of gender, our survival rates appear superior; Table 5 com- 
pares our results with those from Portland, Oregon (154) and a 
recent Coronary Artery Surgery Study (55) series. Figure 3 
attests that our young surgically treated patients fared bette.r at 
every stage than did those in the study of Gertler et al. (22) in 
the era before coronary artery bypass grafting. The c&s& 
approximation of patient and general population surv@al 
curves with increasing age is striking in Figure 3. Paradoxie$l$ , 7 
: 
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survival time after bypass grafting is longer for younger than 
for older patients, bnt the latter gain life expectancies closer to 
the “normal” for their ages; however, this is surely a multifdc- 
torial phenomenon. There may also be several reasons for the 
apparently significant benefit of reoperation, surprisingly re- 
vealed in Figure 5. This phenomenon was shown in Figure 13 
of Lawrie et al. (53) but was not discussed. Perhaps unknown 
preselection factors favor those patients who survive to reop- 
eration. 
Reoperation. Seventeen percent of our patients had one or 
more reoperations. The cumulative incidence (Fig. 2), is smaller 
than in some series, perhaps because of longstanding efforts to 
achieve optimal myocardial revascularization (3.3 grafts/patient 
undergoing a first bypass procedure before 1977). High rates of 
reoperation in the first 2 years after a first bypass procedure 
during or early experience were due to concern for maximal 
planned surgical benefit, which persuaded us to reoperate frc- 
quently for essentially angiographic indications. Some reopera- 
tions might well have been delayed. Happily, except for 2 of 53 
patients, both with major clinical problems, no patient died who 
underwent reoperation before 24 months. Lack of coronary 
angioplasty was another incentive for reoperation; 83% of 40 
reoperations within 12 months of a hrst bypass procedure were 
‘done before angioplasty was available to us. 
The perioperative mortality rate five times greater for 
repeat than for primaty operations is a matter of grave concern. 
We recognize the high risk of mjocardial infarction and death 
due to coronary atheroembolism (36,56,57) at reoperation and 
know that minimizing these events requires meticulous surgical 
technique illuminated by precise information on graft status. The 
handling and disposition of old grafts at reoperation (49,57) is a 
topic of inestimable importance. Loop et al. (49) have reported 
reducing the perioperative mortality rate to <3%, and this is an 
admirable therapeutic goal. 
Care of the bypass graft. Because first causes are as yet 
unalterable, optimal control of risk factors for atherogenesis 
must be ensured. Smoking is a major problem. We (58) 
reported that men continuing to smoke after coronary artery 
bypass grafting had a significantly greater disposition to graft 
atheroscle:osis and occlusion than did nonsmokers; 67% of 
those patients smoked before operation and only 50% had 
stopped smoking 5 years later. Voors et al. (59) have clearly 
demonstrated the clinical consequences. The smoking habit is 
hard to curb. Of 138 military patients 139 years old who 
underwent coronary artery bypass grafting (lo), 88%, or twice 
the proportion in the Canadian Armed Forces study (60) 
smoked before operation and only slightly ~50% had stopped 
5 years later. Control of dyslipidemia may be better, because 
new drugs have changed the odds significantly. Scandinavian 
Simvastatin Survival Study (61), Pravastatin Limitation of 
Atherosclerosis in the Coronary Arteries I (62) and West of 
Scotland Coronary Prevention Study Group (63) (pravastatin) 
studies herald a major therapeutic advance. However, optimal 
utilization of therapy may be the greater challenge (64,65). 
With respect to other drugs, we have given agents affecting 
platelet behavior to all patients undergoing coronary surgery 
since 1969 but have not done a systematic study. Conventional 
long-term anticoagulant therapy in patients with inoperable 
graft disease seems to have been useful, and we believe that 
this treatment option deserves its present attention. Finally, we 
are certain that a dedicated follow-up program of risk factor 
control and early detection of complications is invaluable. 
Unfortunately, the necessary resources are increasingly hard to 
find. 
The conduit. Internal mammary artery grafts, particularly 
from both the left and the right artery together, have come into 
common use quite slowly, but they improve survival (12,66- 
68). The right gastroepiploic artery (69,70) will probably also 
prove to be a valuable long-lasting conduit. Our experience 
with 109 right gastroepiploic artery Vineberg implants (7) and 
a very few, but splendid, bypass grafts has been excellent. We 
are dubious about the inferior epigastric artery and cannot 
comment on the radial arteries as conduits. Synthetic conduits 
have not proved themselves in any hands. Perhaps a superb 
new fabric awaits discovery, but this seems unlikely. The supply 
of arteries is limited and vein grafts will be with us for a long 
time yet. 
Technicalities. Shiley Incorporated (71) recently warned 
that the identity of the person welding outlet struts to valve 
flanges was a “new” risk factor for prosthetic cardiac valve 
failure. Concern for the human variable, led us, in 1983, to 
examine the early patency rates of 424 coronary bypass grafts 
fashioned by five senior surgeons during 1981 to 1982. There 
was no significant difference in overall graft patency for the five 
surgeons, but there were surprising internal variations. The 
most striking was a grade 0 (occlusion) graft incidence rate of 
17% (16 of 94) juxtaposed with a 1% incidence rate of B grades 
for Surgeon X, when the incidence rate of B grades for his four 
colleagues was 5% to 7% (20 of 330). Furthermore, Surgeon X 
had 88% to 92% A ratings for right, left anterior descending 
and marginocircumflex artery grafts, b3t there were 9 occlu- 
sions (56%) without any I3 grades, in 16 grafts to diagonal 
vessels. These branches are fairly accessible and usually less 
important than the parent trunk. We concluded that some 
differences in operative results probably occurred because of 
the heavy responsibility for surgical residency training in a 
teaching hospital. This is a problematic topic, especially in a 
time of surgical “report cards” (72,73), and it may need to be 
addressed formally. 
The bottom line. A quarter-century of efforts in our insti- 
tuticn to alleviate coronary stenosis with coronary artery 
bypass grafting have yielded morbidity, mortality and increased 
life expectancy results at least as good as those reported by 
others. However, all the early promise of coronary bypass 
grafting has not been fulfilled, and an insidiously deadly variety 
of atherosclerosis progressively chokes most vein grafts and, in 
the end, extinguishes their benefit. The clinical consequences 
are evident. Arterial grafts offer better results but have limited 
potential. Many difficult problems in coronary bypass grafting 
remain to be addressed. They include opti:, 1 timing of 
intervention, selection of the best conduits, method,; :f ensur- 
ing technical excellence, control of disease risk factors, moni- 
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taring of long-term graft integrity, prompt detection of those 
requiring reoperation and, not least, methods of ensuring that 
reoperation b as safe as possible. 
We thank our past and present surgical colleagues, Sev:a Aul, MD, Yasar 
Akyurekli. MD, Pierre Bidard, MD, Maurice Brais, MD, Jnderjit Gill, MD, 
William Goldstein, MD, Paul Hendq, MD, Arvind Koshal, MD, Roy Masters. 
MD, without whom there would have been no results. We arc happy to 
acknowledge the indispensable help of Agnes Brach and Catherine Hooper in 
handling data and the inexhaustible patience of Lucie Morio-Brock in preparing 
the manuscript. 
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